靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
GCWB1176 8 Weeks, Multi -Tube, Randomized Assignment, Double -Eye, Placebo Control Human Application Test for Evaluating the Effectiveness and Safety of the Immune Function
This human application test was planned to evaluate the effectiveness and safety of immunodefinition compared to the placebo when the GCWB1176 was consumed for those whose white blood cell level was normal or somewhat decreased.
A Randomized, Parallel-group, Placebo-controlled, Single-blind, Investigator Initiated Trial to Evaluate Efficacy and Safety of LAENNEC (Human Placenta Hydrolysate) Administered by Ultrasonography Guided Subacromial Bursa Injection in Patients With Shoulder Impingement Syndrome
To patients with shoulder collision syndrome, LAENNEC (Human Placenta Hydrolysate) is administered as an injection in the ultrasonic induction underglone, to evaluate the effectiveness and safety.
GCWB1001 12 Weeks, Multi -Tube, Randomized Assignment, Double -Eye, Placebo Control Human Application Test for Evaluating the Effectiveness and Safety of the Respiratory Health Health
This human application test was designed to evaluate the effectiveness and safety of the losing suction tendon, compared to the control food when the GCWB1001 was consistent with the symptoms of the respiratory symptoms of mildness.
100 项与 GREEN CROSS WellBeing Corp. 相关的临床结果
0 项与 GREEN CROSS WellBeing Corp. 相关的专利(医药)
100 项与 GREEN CROSS WellBeing Corp. 相关的药物交易
100 项与 GREEN CROSS WellBeing Corp. 相关的转化医学